Whitehead Institute For Biomedical Research

Whitehead Institute For Biomedical Research, a tax-exempt nonprofit biomedical research organization headquartered in Cambridge, Massachusetts, acts as a prime recipient of federal research grants rather than a federal contractor, conducting foundational and translational life sciences research for the National Institutes of Health and other federal agencies. The Institute operates exclusively in the grant space (94% prime recipient role, 6% sub-recipient role across its recent federal portfolio) and competes under full-and-open mechanisms across multiple NIH institutes and non-NIH agencies without set-aside designations.

The Institute's research portfolio spans molecular and cellular biology, genomics, developmental biology, immunology, and cancer biology. Representative prime grant work includes a $899,850 National Institute of Allergy and Infectious Diseases project grant on host-cell recognition mechanisms in apicomplexan parasite invasion (CFDA 93.855, awarded February 2026, performance through January 2031); a $125,000 National Institute of General Medical Sciences project grant on cell type-specific regulatory mechanisms in untranslated RNA regions and machine learning prediction models (CFDA 93.859, awarded September 2026, performance through August 2028); a $141,750 National Cancer Institute project grant on spatiotemporal tumor microenvironment evolution through prime editing-based lineage tracing (CFDA 93.398, awarded July 2026, performance through June 2028); and a $731,250 Department of the Army Medical Command project grant on macrophage immunotherapy for colorectal cancer (CFDA 12.420, awarded July 2022, performance through May 2025). Sub-recipient work includes collaborations with the Broad Institute on therapeutic prime editing to lower PrP in prion disease, with Dana-Farber Cancer Institute on transcriptional regulation in multiple myeloma, and with Research Triangle Institute and MIT on condensate and splicing biology.

Customer concentration sits heavily with the National Institutes of Health. The top five funding organizations account for 66% of recent awards by count, led by the NIH broadly (92 awards), with NIGMS (23 awards), NCI (21 awards), and NIH sub-agencies serving as anchor customers. DoD accounts for 14 awards across recent activity. The Institute serves 26 distinct federal agencies across its prime and sub footprint. Eighteen awards face ultimate completion inside the next twenty-four months and therefore carry recompete exposure.

Activity has declined modestly over the past five years—ten awards in 2022 to six in both 2025 and 2026—but the Institute maintains deep NIH embeddedness, with combined potential value across all awards reaching $112.5 million and combined dollars obligated reaching $446.6 million (a figure exceeding potential value, reflecting multi-year funding streams and renewals). The Institute's research infrastructure, investigator pool, and peer-review standing within NIH grant processes position it as a stable prime recipient in biomedical science and translational research spaces rather than a federal contractor seeking commercial procurements.